Prothena Corp (PRTA) Stock Price, Quote & News

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antib...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 236 2500

Fax: 353 1 902 3510

Website: www.prothena.com

Address:

77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland

buyandsold Jan. 30 at 8:10 PM

$PRTA really sucks I didnt sell at $11

0 · Reply

Fugazi_ Jan. 28 at 8:05 AM

$PRTA when is the next data release in their pipe? cant find anything

1 · Reply

BillionerOfKing Jan. 19 at 6:01 PM

$PRTA Current Stock Price: $9.35 Contracts to trade: $10 PRTA Feb 20 2026 Call Entry: $0.20 Exit: $0.39 ROI: 97% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

buyandsold Jan. 15 at 3:39 PM

$PRTA i should have trimmed when this was 1/3 of port. But I do see clear path to $30

0 · Reply

OfficialStocktwitsUser Jan. 14 at 4:09 AM

$PRTA RSI: 34.91, MACD: -0.2985 Vol: 0.29, MA20: 9.35, MA50: 10.01 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

buyandsold Jan. 2 at 12:36 PM

$PRTA let's retake $11 in January as funds load up for sales of some assets with special dividends to follow.

1 · Reply

PaperWalletP4 Dec. 26 at 4:23 PM

$PRTA Capital is flowing toward execution strength rather than speculative optionality. Forecast discipline should become more precise and conservative. Sustained traction could validate the investment case. Upside remains tied to tangible progress, not assumptions.

0 · Reply

KurtosisKing Dec. 24 at 12:28 PM

$PRTA Sentiment could pivot sharply depending on how strategic priorities translate into measurable operating outcomes. Delays or dilution could materially reshape the risk profile.

1 · Reply

AIIAAIIA_88 Dec. 19 at 8:57 PM

$PRTA Year end tax loss sells? Disgusting. Very disgusting. LOL

0 · Reply

buyandsold Dec. 17 at 11:05 PM

$PRTA brutality writ large Management should throw us a buyback bone

0 · Reply

Prothena Announces Board of Directors Update

Nov 19, 2025, 4:05 PM EST - 2 months ago

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Nov 11, 2025, 9:00 AM EST - 2 months ago

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Nov 6, 2025, 4:05 PM EST - 3 months ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 30, 2025, 4:05 PM EDT - 3 months ago

Prothena to Report Third Quarter 2025 Financial Results on November 6

Oct 1, 2025, 4:45 PM EDT - 4 months ago

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Aug 28, 2025, 4:05 PM EDT - 5 months ago

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 5 months ago

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Aug 6, 2025, 9:00 AM EDT - 6 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Aug 4, 2025, 4:05 PM EDT - 6 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 28, 2025, 4:05 PM EDT - 6 months ago

Prothena to Report Second Quarter 2025 Financial Results on August 4

Jun 18, 2025, 4:05 PM EDT - 8 months ago

Prothena Announces Corporate Restructuring

Jun 16, 2025, 1:06 AM EDT - 8 months ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

May 27, 2025, 7:43 AM EDT - 8 months ago

Why Is Prothena Stock Trading Lower On Tuesday?

May 23, 2025, 4:05 PM EDT - 9 months ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 9, 2025, 7:16 AM EDT - 9 months ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

RXST SRPT

May 8, 2025, 4:05 PM EDT - 9 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:05 PM EDT - 9 months ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Feb 20, 2025, 8:45 PM EST - 1 year ago

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 17, 2025, 6:10 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 13, 2025, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Dec 19, 2024, 1:05 AM EST - 1 year ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Nov 12, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Sep 27, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Leadership Team Updates

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Prothena to Participate in Upcoming Healthcare Conferences

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

May 28, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Mar 4, 2024, 4:05 PM EST - 2 years ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Feb 23, 2024, 12:31 PM EST - 2 years ago

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 21, 2024, 4:05 PM EST - 2 years ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 15, 2024, 11:53 PM EST - 2 years ago

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 8, 2024, 4:05 PM EST - 2 years ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Jan 8, 2024, 8:30 AM EST - 2 years ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 16, 2023, 11:57 AM EDT - 2 years ago

Prothena prepares for potential sale - Bloomberg News

Sep 21, 2023, 1:39 PM EDT - 2 years ago

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 27, 2023, 7:23 AM EDT - 2 years ago

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Jul 17, 2023, 8:35 AM EDT - 2 years ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 2 years ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 10, 2023, 4:10 PM EDT - 2 years ago

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

buyandsold Jan. 30 at 8:10 PM

$PRTA really sucks I didnt sell at $11

0 · Reply

Fugazi_ Jan. 28 at 8:05 AM

$PRTA when is the next data release in their pipe? cant find anything

1 · Reply

BillionerOfKing Jan. 19 at 6:01 PM

0 · Reply

buyandsold Jan. 15 at 3:39 PM

$PRTA i should have trimmed when this was 1/3 of port. But I do see clear path to $30

0 · Reply

OfficialStocktwitsUser Jan. 14 at 4:09 AM

0 · Reply

buyandsold Jan. 2 at 12:36 PM

$PRTA let's retake $11 in January as funds load up for sales of some assets with special dividends to follow.

1 · Reply

PaperWalletP4 Dec. 26 at 4:23 PM

0 · Reply

KurtosisKing Dec. 24 at 12:28 PM

$PRTA Sentiment could pivot sharply depending on how strategic priorities translate into measurable operating outcomes. Delays or dilution could materially reshape the risk profile.

1 · Reply

AIIAAIIA_88 Dec. 19 at 8:57 PM

$PRTA Year end tax loss sells? Disgusting. Very disgusting. LOL

0 · Reply

buyandsold Dec. 17 at 11:05 PM

$PRTA brutality writ large Management should throw us a buyback bone

0 · Reply

AIIAAIIA_88 Dec. 17 at 1:27 AM

$PRTA Someone is expecting pretty bad news soon. Hmm. I am more bullish. LOL

0 · Reply

buyandsold Dec. 16 at 3:18 PM

$PRTA tought to buy at $11 and be here a week later!

0 · Reply

AIIAAIIA_88 Dec. 16 at 2:16 AM

$PRTA Unusually high AH volume buys today. JMO

2 · Reply

AIIAAIIA_88 Dec. 12 at 10:09 PM

$PRTA The usual Friday strength regardless of the overall market condition over the recent weeks tells me it is getting close! Just saying! LFG 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀

0 · Reply

Quantumup Dec. 10 at 2:04 PM

H.C. Wainwright y'day⬆️ $IMMX's PT to $12 from $8, plus⬆️PoS to 85% and reiterated at a Buy rating. $PRTA $AZN $JNJ ABBV $TAK BMY SNY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/1998754299422122357?s=20

0 · Reply

SuperGreenToday Dec. 9 at 5:59 PM

$PRTA Share Price: $10.53 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $1.53 – $1.89 Target Zone: $2.65 – $3.23 Potential Upside: 63% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

AIIAAIIA_88 Dec. 5 at 8:43 PM

$PRTA What is it with the short sellers and bears who cannot tolerate seeing this stock over $11 for a day??!! They will be kicking and crying soon enough. JMO

1 · Reply

AIIAAIIA_88 Dec. 3 at 8:49 PM

https://stocktwits.com/news-articles/markets/equity/bristol-myers-stock-jumps-as-wall-street-backs-added-enrollment-in-alzheimer-s-trial/cLIXwRaRE1p This is with $PRTA drug candidate for AD. Incredible that the article does not mention $PRTA. But I know! This is why the stock is up almost 10% today.

1 · Reply

AIIAAIIA_88 Dec. 3 at 2:42 PM

$PRTA Please be like CAPR soon. Very soon! 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥

0 · Reply

AIIAAIIA_88 Dec. 1 at 2:52 PM

$PRTA The AD + PD winner, I am sure of. Everyone thought that this one was dead earlier this year. Not by a long shot, nope. It is still alive and kicking! You will see very soon. JMO

0 · Reply

JarvisFlow Dec. 1 at 1:17 PM

Citizens updates rating for Prothena Corp ( $PRTA ) to Market Outperform, target set at 11 → 19.

0 · Reply

Market Cap	487.70M
Revenue (ttm)	135.16M
Net Income (ttm)	-122.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	45.25
Profit Margin	-90.49%
Debt to Equity Ratio	0.00

Volume	389,900
Avg Vol	619,720
Day's Range	N/A - N/A
Shares Out	53.83M
Stochastic %K	9%
Beta	-0.09
Analysts	Sell
Price Target	$20.33